1. Otani K, Tanaka O, Kaneko S, Ishida M, Yasui N, Fukushima Y, “Mechanisms of the development of trazodone withdrawal symptoms.” International Clinical Pharmacology Journal [Internet] 1994 Summer [cited 2023 May 8]
2. Jarema M, Dudek D, Landowski J, Heitzman J, Rabe-Jablonska J, Rybakowski J, “Trazodon — the antidepressant: mechanism of action and its position in the treatment of depression.” Polish Journal of Psychiatry 2011 Jul-Aug [cited 2023 May 8]
3. FDA trazodone label, “Highlights of Prescribing Information“, Revised 2017 Jun [cited 2023 May 8]
4. Jaffer KY, Chang T, Vanle B, Dang J, Steiner A, Loera N, et al., “Trazodone for Insomnia: A Systematic Review.” Innovations in Clinical Neuroscience 2017 Jul-Aug [cited 2023 May 8]
5. Mendelson W, “A review of the evidence for the safety of trazodone in insomnia.” Journal of Clinical Psychiatry 2005 Apr [cited 2023 May 8]
6. Shin JJ, Saadabadi A. Trazodone. [Updated 2020 May 28]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021 Jan-.Available from: https://www.ncbi.nlm.nih.gov/books/NBK470560/ [cited 2023 May 8]
7. Knobler HY, Itzchaky S, Emanuel D, Mester R, Maizel S. Trazodone-induced mania. Br J Psychiatry. 1986 Dec;149:787-9. doi: 10.1192/bjp.149.6.787. PMID: 3790881 [cited 2023 May 8]
8. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019 May 17;116(20):355-361. doi: 10.3238/arztebl.2019.0355. PMID: 31288917; PMCID: PMC6637660. [cited 2023 May 8]
9. Montalbetti D, Zis A, “Cholinergic Rebound Following Trazodone Withdrawal.” Journal of Psychopharmacology Feb 88 Vol 8 Issue 1 P.73 [cited 2023 May 8]
10. Lejoyeux M, Adès J. Antidepressant discontinuation: a review of the literature. J Clin Psychiatry. 1997;58 Suppl 7:11-5; discussion 16. PMID: 9219488. [cited 2023 May 8]
11. Lerner A, Klein M, “Dependence, withdrawal, and rebound of CNS drugs – an update.” Oxford Academic Journal: Brain Communications Vol 1 Issue 1 2019 [cited 2023 May 8]
12. FDA label Oleptro (trazodone hydrochloride) extended release tablets [Feb 2010] [cited 2023 May 8]
13. Hengartner MP, Schulthess L, Sorensen A, Framer A. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives from a large internet forum. Ther Adv Psychopharmacol. 2020;10:2045125320980573. Published 2020 Dec 24. doi:10.1177/2045125320980573 [cited 2023 May 8]
14. Bossini L, Coluccia A, Casolaro I, Benbow J, Amodeo G, De Giorgi R, Fagiolini A. Off-Label Trazodone Prescription: Evidence, Benefits and Risks. Curr Pharm Des. 2015;21(23):3343-51. doi: 10.2174/1381612821666150619092236. PMID: 26088119. [cited 2023 May 8]
15. Schwasinger-Schmidt TE, Macaluso M. Other Antidepressants. Handb Exp Pharmacol. 2019;250:325-355. doi: 10.1007/164_2018_167. PMID: 30194544. [cited 2023 May 8]
16. Gonçalo AMG, Vieira-Coelho MA. The effects of trazodone on human cognition: a systematic review. Eur J Clin Pharmacol. 2021 Jun 7:1–15. doi: 10.1007/s00228-021-03161-6. Epub ahead of print. PMID: 34097124; PMCID: PMC8182348. [cited 2023 May 8]
17. Fagiolini A, Comandini A, Catena Dell’Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs. 2012 Dec;26(12):1033-49. doi: 10.1007/s40263-012-0010-5. Erratum in: CNS Drugs. 2013 Aug;27(8):677. PMID: 23192413; PMCID: PMC3693429. [cited 2023 May 8]
18. Lefkowitz D, Kilgo G, Lee S. Seizures and Trazodone Therapy. Arch Gen Psychiatry. 1985;42(5):523. doi:10.1001/archpsyc.1985.01790280105012 [cited 2023 May 8]
19. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013;13(4):533-540. [cited 2023 May 8]
20. Bijl D. The serotonin syndrome. Neth J Med. 2004 Oct;62(9):309-13. PMID: 15635814. [cited 2023 May 8]
21. Bossini L, Casolaro I, Koukouna D, Cecchini F, Fagiolini A. Off-label uses of trazodone: a review. Expert Opin Pharmacother. 2012 Aug;13(12):1707-17. doi: 10.1517/14656566.2012.699523. Epub 2012 Jun 20. PMID: 22712761. [cited 2023 May 8]
22. FDA label Trazodone hydrochloride tablets for oral use. Approval 1981 [cited 2023 May 8]
23. Jackson E, Shoemaker R, Larian N, Cassis L. Adipose Tissue as a Site of Toxin Accumulation [published correction appears in Compr Physiol. 2018 Jun 18;8(3):1251]. Compr Physiol. 2017;7(4):1085-1135. Published 2017 Sep 12. doi:10.1002/cphy.c160038 [cited 2023 May 8]
24. Roth AJ, McCall WV, Liguori A. Cognitive, psychomotor and polysomnographic effects of trazodone in primary insomniacs. J Sleep Res. 2011 Dec;20(4):552-8. doi: 10.1111/j.1365-2869.2011.00928.x. Epub 2011 May 30. PMID: 21623982; PMCID: PMC3165092. [cited 2023 May 8]
25. Friedmann PD, Rose JS, Swift R, Stout RL, Millman RP, Stein MD. Trazodone for sleep disturbance after alcohol detoxification: a double-blind, placebo-controlled trial. Alcohol Clin Exp Res. 2008;32(9):1652-1660. doi:10.1111/j.1530-0277.2008.00742.x [cited 2023 May 8]
26. Bryant SG, Ereshefsky L. Antidepressant properties of trazodone. Clin Pharm. 1982 Sep-Oct;1(5):406-17. PMID: 6764164.[cited 2023 May 8]